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Background: People living with HIV may be at increased risk for infections with resistant organisms. Infections
with ESBL-producing organisms are of particular concern because they limit treatment options for severe
Gram-negative infections in low-resource settings.
Objectives: To investigate the association between HIV status and urinary tract infections (UTIs) with ESBL-
producing Escherichia coli.
Patients and methods: Cross-sectional study enrolling adults presenting with UTI symptoms to primary care
clinics in Harare, Zimbabwe. Demographic and clinical data were collected during interviews and a urine sample
was collected for culture from each participant. Antimicrobial susceptibility testing was performed according to
EUCAST recommendations.
Results: Of the 1164 who were enrolled into the study, 783 (64%) were female and 387 (33%) were HIV
infected. The median age was 35.8 years. Urine cultures were positive in 338 (29.0%) participants, and the
majority of bacterial isolates were E. coli (n"254, 75.2%). The presence of ESBL was confirmed in 49/254
(19.3%) E. coli. Participants with HIV had a 2.13 (95% CI 1.05–4.32) higher odds of infection with ESBL-producing
E. coli than individuals without HIV. Also, the prevalence of resistance to most antimicrobials was higher among
participants with HIV.
Conclusions: This study found an association between HIV and ESBL-producing E. coli in patients presenting
with symptoms suggestive of UTI to primary care in Harare. HIV status should be considered when prescribing
empirical antimicrobial treatment.
Introduction
The increase in antimicrobial resistance (AMR) challenges our abil-
ity to effectively treat infections leading to excess morbidity and
mortality.1 Although AMR has been highlighted as a priority on the
global health agenda,2 surveillance data on the burden of AMR are
lacking from many low- and middle-income countries (LMICs).3
In understanding the burden of AMR, specific attention needs
to be paid to populations who may be at increased risk for
infections with resistant organisms such as people living with HIV.
Globally, there are currently 38 million people living with HIV;
two-thirds in sub-Saharan Africa.4 Although there is evidence of an
association between HIV and infection and colonization with resist-
ant organisms, research has mainly focused on Gram-positive
pathogens while data for Gram-negative infections are sparse.5–7
ESBL-producing Gram-negative organisms are of particular
concern in LMICs. ESBLs confer resistance to third-generation
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cephalosporins, which are the drugs of choice for the treatment of
severe Gram-negative infections.8 A better understanding of
the epidemiology of AMR allows optimization of treatment recom-
mendations with the ultimate aim of improving patient
management.
Urine cultures performed in outpatients with symptoms of urin-
ary tract infection (UTI) allow estimation of the burden of commu-
nity-level Gram-negative resistance. The most frequently isolated
organism from urine is Escherichia coli,9 which is also the main
cause of Gram-negative sepsis10 and a WHO priority pathogen for
AMR surveillance.3
This study aimed to investigate the association between HIV
status and UTIs with ESBL-producing E. coli and to investigate the
prevalence of AMR in bacteria causing UTIs among adults present-
ing to primary healthcare clinics (PHCs) in Harare, Zimbabwe.
Patients and methods
Ethics
Ethical approval for the ARGUS study was obtained from the Medical
Research Council Zimbabwe (MRCZ/A/2406), the Institutional Review Board
of the Biomedical Research and Training Institute in Zimbabwe and the
London School of Hygiene and Tropical Medicine Ethics committee (Ref.
16424). The research was conducted in accordance with the Declaration of
Helsinki and national and institutional standards. All study participants
provided written informed consent.
Study setting and participants
Data were collected as part of the Antimicrobial Resistance in Gram-nega-
tive bacteria from Urinary Specimens (ARGUS) study.11 This was a cross-sec-
tional analysis of consecutively enrolled participants recruited from 10
PHCs in southwest Harare between 1 July 2019 and 24 July 2020. Adult HIV
prevalence in Zimbabwe is estimated at 13%.4 According to national guide-
lines UTIs should be treated with either a fluoroquinolone or amoxicillin.12
Eligibility criteria included age 18 years or older, having at least two
symptoms suggestive of UTI, onset of symptoms within the previous
2 weeks, presence of symptoms within the last 24 h, and provision of
written informed consent. Those who were discharged from hospital in the
previous 72 h, who had a urinary catheter in situ or who were enrolled into
the study on a previous occasion were excluded.
Interviewer-administered questionnaires determined potential risk
factors for AMR and clinical history. Responses were entered in electronic
form using the Open Data Kit (ODK, www.opendatakit.org). HIV status was
ascertained by self-report and confirmed by patient-held records.
Laboratory methods
A mid-stream urine sample was collected from every participant and trans-
ported to the laboratory within 4 h of collection. A volume of 1 lL of the
sample was inoculated on chromogenic agar (Brilliance UTI agar, Oxoid,
UK) and incubated at 37 C for 24 h. Bacterial identification was performed
using chromogenic media and APIs (Analytical Profile Index, bioMérieux,
France) for Enterobacterales other than E. coli. Urine cultures were consid-
ered positive if there was growth of103 cfu/mL of a uropathogen either in
pure culture or when a uropathogen was predominant. Antimicrobial sus-
ceptibility testing (AST) was done by disc diffusion using the Kirby-Bauer
method and interpreted using EUCAST standards.13 Testing for ESBL and
AmpC production was performed according to EUCAST recommenda-
tions.14 ATCC reference isolates were used for quality control of bacterial
identification and AST (for further details on laboratory testing see
Supplementary data, available at JAC-AMR Online).
The v2 test was used to evaluate categorical variables. Differences be-
tween continuous variables were assessed using the Mann–Whitney U-
test. The level of significance was considered to be P0.05. For the associ-
ation between HIV infection and infection with ESBL-producing E. coli, a
multivariate analysis using logistic regression was performed (Figure S1).
The model excluded individuals with unknown HIV status. Statistical analy-
ses were performed using STATA v.15 (StataCorp, TX, USA).
Data availability
All data are presented in the main manuscript and additional supporting files.
Data can also be provided on reasonable request to the corresponding author.
Results
Of the 1374 individuals with UTI symptoms presenting at the clin-
ics, 1164 were eligible and were enrolled into the study. Reasons
for ineligibility are detailed in Figure S2.
The median age was 35.8 years (IQR 26.3–47.7) and 743
(63.8%) were female of whom 102 (13.7%) were pregnant
(Table 1).
The study included 387 (33.2%) participants with HIV infection,
680 who were HIV negative and 97 (8.3%) who did not know their
HIV status. ART coverage among participants with HIV was 97.2%
and 214 (55.6%) were receiving co-trimoxazole prophylaxis.
Uropathogens and AMR
Cultures were positive in 338 (29.0%) participants, 761 (65.4%)
were negative and 65 (5.6%) contaminated. The majority of bac-
terial isolates were E. coli (n"254, 75.2%) followed by other coli-
forms (n"33, 9.8%), Enterococcus spp. (n"40, 11.8%),
Staphylococcus saprophyticus (n"3, 0.9%) and Staphylococcus
aureus (n"2, 0.6%).
The prevalence of resistance to first-line antimicrobials was
245 (79.0%) for amoxicillin and 66 (19.8%) for ciprofloxacin. Co-
trimoxazole resistance was present in 247 (84.0%) of isolates.
Table S3 shows the prevalence of resistance according to bacterial
species. In Enterobacterales resistance to amoxicillin/clavulanic
acid was 40.1% (117/292), to nitrofurantoin 9.6% (28/292) and to
fosfomycin 2.2% (5/228). Ceftriaxone resistance was present in
52/292 (17.8%) of isolates. The presence of ESBL was confirmed
in 49/254 (19.3%) E. coli. Exposure to fluoroquinolones in the pre-
vious year but not to other antimicrobials was also associated
with infections with ESBL-producing E. coli (20.4% versus 4.4% for
no prior exposure, P , 0.001, Table S5). ESBL-producing E. coli
were resistant to ciprofloxacin, gentamicin, nitrofurantoin and
fosfomycin in 69.4% (34/49), 30.6% (15/49), 18.4% (9/49) and
9.8% (4/41) of isolates, respectively.
HIV and AMR in E. coli
Amoxicillin resistance was present in 67 (81.7%) E. coli isolates
from participants with HIV and in 117 (80.7%, P"0.851) from
individuals without HIV infection while ciprofloxacin resistance
was detected in 24 (29.3%) and 27 (18.6%, P"0.065), respect-
ively (Figure 1). The prevalence of co-trimoxazole resistance was
91.5% among individuals with HIV and 86.9% in those without
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HIV infection. In participants with HIV who were taking co-tri-
moxazole prophylaxis the prevalence of co-trimoxazole resist-
ance was 97.8%. Infections with ESBL-producing organisms
were more common among participants with HIV than in partici-
pants without HIV infection (26.8% versus 13.1%, P"0.010).
Participants with HIV had a 2.43 (95% CI 1.22–4.83) higher odds
of infection with ESBL-producing E. coli than individuals without
HIV, and the association persisted after adjusting for age and
sex (adjusted OR (aOR) 2.13; 95% CI 1.05–4.32, Tables S5 and S6,
Figure S1).
Discussion
This study shows a high prevalence of resistance to first-line antibi-
otics for UTI treatment and of ESBL-producing E. coli among indi-
viduals presenting with symptoms suggestive of UTIs to PHCs in
Harare. Also, the study found an association between HIV infection
and the presence of ESBL-producing E. coli in this setting. In gen-
eral, the prevalence of resistance was higher in participants with
HIV infection compared with those without for almost all antimi-
crobials tested.
Table 1. Characteristics of individuals presenting with symptoms of UTI to public health clinics in Harare, Zimbabwe, stratified by urine culture result
Characteristic
Urine culture result
total, N"1164 positive, N"338 negative, N"761 contamination, N"65
Age, years, median (IQR) 35 (26–48) 34 (25–50) 36 (27–47) 34 (25–47)
Female sex, n (%) 743 (63.8) 263 (77.8) 431 (56.6) 49 (75.4)
Pregnancy, n (%)a
not pregnant 599 (81.9) 222 (85.4) 341 (80.8) 36 (73.5)
first trimester 19 (1.6) 9 (2.7) 9 (1.2) 1 (1.5)
second trimester 32 (2.7) 8 (2.4) 20 (2.6) 4 (6.2)
third trimester 49 (4.2) 7 (2.1) 35 (4.6) 7 (10.8)
unknown 30 (4.1) 14 (5.4) 15 (3.6) 1 (2.0)
Place of recruitment, n (%)
acute clinic 840 (72.2) 258 (76.3) 539 (70.8) 43 (66.2)
maternity 85 (7.3) 17 (5.0) 56 (7.4) 12 (18.5)




7 (4–12) 7 (3–10) 7 (5–12) 7 (5–12)
reported fever, n (%)b 122 (10.6) 36 (10.8) 79 (10.5) 7 (10.9)
dysuria, n (%) 942 (81.8) 295 (88.1) 595 (79.1) 52 (81.3)
frequency, n (%) 824 (71.6) 261 (77.9) 515 (68.5) 48 (75.0)
suprapubic pain, n (%) 730 (63.4) 193 (57.6) 490 (65.2) 47 (73.4)
haematuria, n (%) 185 (18.8) 77 (23.0) 96 (12.8) 12 (18.8)
limitation of daily activ-
ities, n (%)
168 (14.6) 60 (17.9) 99 (13.2) 9 (14.1)
Comorbidities, n (%)
diabetes 23 (2.0) 8 (2.4) 13 (1.8) 2 (3.1)
chronic kidney disease 10 (0.9) 3 (0.9) 7 (0.9) 0 (0)
hypertension 126 (11.0) 42 (12.6) 78 (10.5) 6 (9.2)
HIV infection, n (%)c 387 (36.3) 110 (36.5) 259 (36.8) 18 (29.0)
co-trimoxazole prophy-
laxis, n (%)d
214 (55.6) 58 (52.7) 145 (56.4) 11 (61.1)
on ART, n (%)d 351 (97.2) 99 (97.1) 237 (97.9) 15 (88.2)
Outcome of their clinic visit, n (%)
discharged home 1069 (97.9) 318 (98.8) 691 (97.6) 60 (96.8)
referred to outpatient 12 (1.1) 4 (1.2) 8 (1.1) 0 (0)
specialist
referred to hospital 11 (1.0) 0 (0) 9 (1.3) 2 (3.2)
Missing data: clinical symptoms (n"13: duration of symptoms, fever, dysuria, frequency, suprapubic pain, haematuria, limitation of daily activities);
comorbidities (n"23: diabetes, chronic kidney disease, hypertension); ART (n"26); outcome of the clinic visit (n"72).
aDenominator: women.
bFor 939 (80.7%) participants a temperature measurement was available and 44 (4.7%) had an axillary temperature of 37.5 C.
c97 patients did not know their HIV status.
dDenominator: participants with HIV infection.
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Almost one in five of all study participants, and one in four of
those with HIV infection, had a UTI due to ESBL-producing E. coli.
The prevalence of ESBL among participants with HIV was 2-fold
higher compared with those without. While resistance to third-
generation cephalosporins is less important in primary care
settings the associated resistance to oral antimicrobials limits
treatment options in outpatients. Furthermore, a high ESBL preva-
lence in the community setting will translate to high levels of
infections due to ESBL-producing organisms among severely ill
patients admitted to hospital. This is particularly problematic since
third-generation cephalosporins are reserved for the treatment of
severe Gram-negative infections in hospitalized patients and alter-
native treatment options such as carbapenems are not easily
available or affordable in most LMICs. This is compounded by lim-
ited access to laboratory diagnostics that would enable diagnosis
of infections with resistant organisms to guide targeted antibiotic
treatment.
Bacterial infections remain a major cause of hospitalization and
death among people living with HIV.15 The higher prevalence of
ESBL-producing E. coli infections among participants with HIV may
be explained by the more frequent healthcare seeking in this
group leading to colonization and infection with resistant organ-
isms. Comorbidities, hospital admissions, clinic visits and anti-
microbial prescriptions, which are well-recognized risk factors for
infections with resistant pathogens, are more common in those
infected with HIV compared with those without.16–19 HIV status
therefore should be taken into consideration when prescribing
antimicrobials.
In this study, there was a high prevalence of resistance to first-
line treatment. This is not surprising given the frequent use of
amoxicillin for a broad range of indications. Furthermore, the
high prevalence of co-trimoxazole resistance can be explained
by its use as prophylaxis in HIV-infected individuals.20 On the
other hand, the prevalence of resistance to nitrofurantoin was
,10%, making it an effective and affordable treatment option for
uncomplicated infections in this setting at a cost per treatment of
approximately $1. Fosfomycin would serve as a good alternative
for treatment given the low prevalence of resistance, low cost
(around $5), and single-dose treatment regimens.
This study focused on patients presenting to primary care facili-
ties, providing a good estimate for community-level resistance
prevalence in Harare. The study recruited from 10 PHCs in the
largest city in Zimbabwe across different socioeconomic strata,
making the results generalizable to the urban population of
Harare. Antimicrobials taken prior to clinic presentation may have
led to an overestimation of resistance. Furthermore, the study was
underpowered to detect an association between HIV and AMR
other than ESBL.
This study found an association between HIV and
ESBL-producing E. coli in patients presenting with symptoms
suggestive of UTI to primary care in Harare. HIV status should be
considered when prescribing empirical antimicrobial treatment
in this setting to ensure effective treatment for both in- and
outpatients. The high prevalence of resistance to first-line anti-
microbials highlights the urgent need for up-to-date data on
AMR prevalence to inform antimicrobial treatment guidelines.
Consolidating laboratory capacity, strengthening AMR surveil-
lance and promoting research in AMR in LMICs is paramount to
ensure treatment guidelines are tailored to the local context
and epidemiology.
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